



Application No. 09/534,960

Attorney Docket No. 1009-US

B1 Fw
1615

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

On September 15, 2005
Date

Ann Marie McElligott

Signature

Ann Marie McElligott

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

1. Certificate of Mailing;
2. Information Disclosure Statement Transmittal Letter;
3. Information Disclosure Statement (2 pages); and
4. Return Receipt Postcard.

09/22/2005 DEMMANU1 00000014 502392 09534960

01 FC:1806 180.00 DA



Attorney Docket No. 1009-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moros, Daniel et al.

Application No: 09/534,960

Art Unit: 1615

Filed: 03-27-2000

Examiner: Sharon Lee Howard

For: Controlled Delivery System of antifungal and
Keratolytic Agents for Local Treatment of Fungal
Infections

Customer No: *35159*
35159

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to the patentability of the claims of the above-identified application.

In accordance with M.P.E.P. §609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


The present Information Disclosure Statement is being submitted in compliance with 37 C.F.R. §1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the

results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. §1.104(a) and in the course of each search, will review for relevance every document cited on the attached from even if not initialed.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

The present Information Disclosure Statement is being filed under 37 C.F.R. §1.97(c). The Commissioner is authorized to charge Deposit Account No. 50-2392, in the name of Taro Pharmaceuticals, the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement. Additionally, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 50-2392, in the name of Taro Pharmaceuticals.


Respectfully submitted,



Donna A. Robertson-Chow, Ph.D.
Reg. No. 47,030
Taro Pharmaceuticals U.S.A., Inc.
Five Skyline Drive
Hawthorne, New York 10532

Date: September 14, 2005

Telephone: (914) 345-9001
Facsimile: (914) 347-5376



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	09/534,960
Filing Date	03-27-2000
First Named Inventor	Friedman, Michael
Art Unit	1615
Examiner Name	Sharon Lee Howard
Attorney Docket Number	1009-US

Sheet	1	of	1
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

